Merit Medical Systems (NASDAQ:MMSI – Get Free Report) is projected to post its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of $0.96 per share and revenue of $405.2450 million for the quarter. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.
Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.10. The firm had revenue of $381.88 million during the quarter, compared to analyst estimates of $377.59 million. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. Merit Medical Systems’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.86 earnings per share. On average, analysts expect Merit Medical Systems to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Merit Medical Systems Stock Performance
Shares of NASDAQ MMSI opened at $76.10 on Tuesday. The company has a market cap of $4.54 billion, a P/E ratio of 32.94, a P/E/G ratio of 2.31 and a beta of 0.52. Merit Medical Systems has a 52-week low of $59.74 and a 52-week high of $94.75. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.46 and a current ratio of 5.08. The firm’s fifty day moving average is $68.44 and its two-hundred day moving average is $71.89.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on Merit Medical Systems
Insider Activity at Merit Medical Systems
In other news, insider Brian G. Lloyd bought 2,000 shares of the stock in a transaction on Thursday, May 7th. The stock was acquired at an average cost of $62.62 per share, for a total transaction of $125,240.00. Following the acquisition, the insider owned 2,000 shares of the company’s stock, valued at $125,240. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lynne N. Ward sold 5,000 shares of Merit Medical Systems stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $62.61, for a total value of $313,050.00. Following the completion of the sale, the director owned 7,809 shares of the company’s stock, valued at $488,921.49. The trade was a 39.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.70% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC bought a new stake in shares of Merit Medical Systems in the 4th quarter valued at about $25,000. Danske Bank A S bought a new position in Merit Medical Systems in the third quarter worth approximately $42,000. Quarry LP lifted its holdings in Merit Medical Systems by 185.9% during the third quarter. Quarry LP now owns 526 shares of the medical instruments supplier’s stock worth $44,000 after buying an additional 342 shares during the period. Global Retirement Partners LLC boosted its position in Merit Medical Systems by 973.6% during the 4th quarter. Global Retirement Partners LLC now owns 569 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 516 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Merit Medical Systems by 745.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock valued at $86,000 after acquiring an additional 813 shares during the period. Hedge funds and other institutional investors own 99.66% of the company’s stock.
Merit Medical Systems Company Profile
Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
Featured Articles
- Five stocks we like better than Merit Medical Systems
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
